全文获取类型
收费全文 | 21540篇 |
免费 | 1635篇 |
国内免费 | 227篇 |
专业分类
耳鼻咽喉 | 177篇 |
儿科学 | 758篇 |
妇产科学 | 407篇 |
基础医学 | 2879篇 |
口腔科学 | 348篇 |
临床医学 | 2234篇 |
内科学 | 4338篇 |
皮肤病学 | 284篇 |
神经病学 | 2015篇 |
特种医学 | 725篇 |
外国民族医学 | 3篇 |
外科学 | 2585篇 |
综合类 | 1213篇 |
现状与发展 | 2篇 |
一般理论 | 7篇 |
预防医学 | 1658篇 |
眼科学 | 672篇 |
药学 | 1237篇 |
2篇 | |
中国医学 | 350篇 |
肿瘤学 | 1508篇 |
出版年
2022年 | 195篇 |
2021年 | 367篇 |
2020年 | 247篇 |
2019年 | 304篇 |
2018年 | 333篇 |
2017年 | 305篇 |
2016年 | 331篇 |
2015年 | 401篇 |
2014年 | 527篇 |
2013年 | 709篇 |
2012年 | 1102篇 |
2011年 | 1190篇 |
2010年 | 822篇 |
2009年 | 765篇 |
2008年 | 971篇 |
2007年 | 1093篇 |
2006年 | 1060篇 |
2005年 | 930篇 |
2004年 | 906篇 |
2003年 | 754篇 |
2002年 | 780篇 |
2001年 | 676篇 |
2000年 | 679篇 |
1999年 | 496篇 |
1998年 | 210篇 |
1997年 | 180篇 |
1996年 | 154篇 |
1995年 | 176篇 |
1994年 | 161篇 |
1993年 | 146篇 |
1992年 | 437篇 |
1991年 | 408篇 |
1990年 | 409篇 |
1989年 | 356篇 |
1988年 | 353篇 |
1987年 | 340篇 |
1986年 | 351篇 |
1985年 | 316篇 |
1984年 | 274篇 |
1983年 | 229篇 |
1982年 | 165篇 |
1981年 | 162篇 |
1980年 | 137篇 |
1979年 | 219篇 |
1978年 | 188篇 |
1977年 | 138篇 |
1976年 | 139篇 |
1975年 | 143篇 |
1974年 | 166篇 |
1973年 | 163篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
2.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
3.
目的 探讨P16、P15、P14基因5'CpG岛在膀胱移行细胞癌中甲基化状态及其临床意义。方法 应用甲基化特异性PCR(methylation—specific PCR,MSP)方法检测40例膀胱移行细胞癌P16、P15、P14基因甲基化程度,χ^2检验分析其甲基化程度与膀胱癌病理分级分期间关系。结果 膀胱移行细胞癌P16、P15、P14 5'CpG岛甲基化扩增阳性化率分别为27.5%、17.5%、35%,而正常膀胱组织中均未检测到三种基因5'CpG岛甲基化。P16、P14基因甲基化与膀胱癌病理分级分期有显著性差异(P〈0.05),P15基因则没有显著性差异(P〉0.05)。结论 P16、P15、P14基因在膀胱癌组织中的甲基化率较高,三种抑癌基因5'CpG岛异常高甲基化,在膀胱癌的发生、发展中具有重要作用。 相似文献
4.
5.
6.
7.
8.
F Elferink W J van der Vijgh W W ten Bokkel Huinink J B Vermorken I Klein B Winograd M K Knobf G Simonetti H E Gall J G McVie 《British journal of cancer》1987,56(4):479-483
Pharmacokinetics of the cis-platin analog ethylenediaminemalonatoplatinum(II) (JM-410) was studied in 28 cycles of 19 patients during the phase I study of this drug. The drug was administered intravenously by short-term (10-60 min) infusion. Doses ranged from 20 to 1,200mg m-2. JM-40 was determined in plasma ultrafiltrate and urine by HPLC. Platinum (Pt) concentrations were determined in plasma, plasma ultrafiltrate, urine and red blood cells by atomic absorption spectrometry up to 5 days after administration of the drug. Ultrafilterable Pt could be determined up to 45 days after the infusion in one patient sampled over such a long period. Pharmacokinetics of JM-40 showed a linear behaviour. The final half-life of total Pt in plasma was 4.1 +/- 0.9 days. The disposition of JM-40 was similar to that of ultrafilterable Pt in respect to t1/2 alpha (10 and 13 min), t1/2 beta (44 and 57 min), volumes of distribution Vc (11 and 121) and Vss (17 and 201), systemic clearance (256 and 223 ml min-1), renal clearance (69 and 73 ml min-1) and metabolic clearance (183 and 154 ml min-1). During the first 6 h 27 +/- 9% of the administered dose was excreted as JM-40. Cumulative platinum excretion in the urine amounted to 29 +/- 13% and 60 +/- 13% over the first 6 h, 24 h and 5 days, respectively. The uptake of platinum in red blood cells was limited, comprising only 0.24 +/- 0.12% of the administered dose. Although JM-40 and carboplatin are structurally closely related, pharmocokinetics and toxicity of JM-40 were more similar to cis-platin than to carboplatin. 相似文献
9.
Lester A. Klein 《Neurourology and urodynamics》1987,6(2):95-99
The trigone sensitivity test, a complementary test to cystometry, has been proposed as a method for distinguishing certain clinical disorders. Pressure is applied to the trigone region of the bladder by pulling upon a Foley catheter with the balloon inflated and the amount of force needed to induce an urge to void is recorded. Although the trigone sensitivity test has been proposed as a test of exteroceptive function, it is possible that deeper receptors, perhaps proprioceptors, are actually responsible for the awareness of the urge to void during the study. The present investigation compared the trigone sensitivity test with provoked detrusor contraction in 107 patients. The findings indicate that variations in the two responses occur independently of each other. It is concluded that different neural pathways are responsible for the two functions. The hypothesis that exteroceptive and not proprioceptive nerves are being measured during trigone sensitivity testing is supported by these findings. 相似文献
10.